



Supply constraint of Creon® (pancreatin)

19th July 2024

As the marketing authorisation holder and distributor of Creon® in the UK, we were notified by our third-party manufacturing partner, Abbott, of a global supply constraint of Creon®. This constrained supply is due to high global demand and reaching maximum manufacturing supply output. Due to this, our third-party manufacturing partner's current production is unable to meet all demand.

The constrained supply is not due to any quality, safety or efficacy issues of Creon® being produced.

In the UK, Creon® strengths 25,000 and 10,000 are in constrained supply. However, our current expectation is that during this period of constraint, we will be able to meet the majority of demand. ViatriS is currently receiving continuous supply of Creon® from Abbott. Distribution of all marketed strengths of Creon® from Abbott to our distribution partner and onwards to pharmacies in the UK will continue as shipments arrive.

To try to ensure that there is a broad distribution of all Creon® strengths across UK pharmacies, we have agreed to place quotas on the number of packs each individual pharmacy can order. For more information on the quotas in place, please speak with your wholesaler to discuss this. If the quotas are below your regular monthly usage, please let your wholesaler know.

We are committed to providing reliable access to medicines for our patients, and fully appreciate how important this medicine is for individuals who rely on pancreatic enzyme replacement therapy (PERT) and understand the challenges this situation poses for patients and their healthcare professionals.

As part of the actions taken to mitigate the impact of the shortage on patients and healthcare professional, ViatriS UK has initiated a free Creon® customer service line dedicated to patients and healthcare professional affected by Creon® supply constraints.

If you require additional information or have any questions, please contact the Creon customer service helpline on **0800 8086410** or via email; productenquiries@viatris.com. For medical enquiries please contact our medical information team on 01707 853 000 or via email; info.uk@viatris.com

Yours sincerely,
Mohammed Shehzad
Therapy Area Lead ViatriS

UK-CRE-2024-00013 July 2024

This email is intended for UK healthcare professionals. Please continue to report suspected adverse drug reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions online via the Yellow Card website: <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to

FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, at the back of the British National Formulary (BNF), by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report adverse reactions direct to the marketing authorisation holder at pv.uk@viatris.com.